Selection of current studies
-
Evaluation of TAVR & Optimal Heart Failure Therapy (OHFT) versus OHFT in HF patients
600 patients, USA, Europe & Canada
Services: protocol, statistics, monitoring EU, CEC adjudication, DSMB, safety reporting EU and ECG Core Lab
-
First in Man: Biodegradable polymer Sirolimus‐eluting stent (Chinese)
132 patients, Europe
Full-service including Core Lab
-
Post-marketing VT ablation study
382 patients, Europe and US
Regulatory Submission, Site Monitoring & Management and Safety reporting Europe
-
Evaluation of NOAC in Patients after Successful Transcatheter Aortic Valve Implantation (TAVI)
1,500 patients, Europe & US
Full-service
-
Bioresorbable scaffold
2,690 patients, Europe
Services: CEC adjudication and SYNTAX Score analysis
-
High Bleeding Risk patients
4,300 patients, Global
Services: CEC adjudication, DSMB, Safety Reporting and Site Management BENELUX
-
Drug Eluting Stent - click here for trial details
1,400 patients, Europe
Services: Full study including OCT sub-study
-
Transcatheter aortic valve implantation
2,500 patients, global
Services: protocol, CEC adjudication and DSMB
-
Hybride surgical ablation
210 patients, Europe
Services: monitoring, regulatory submission, safety reporting, CEC adjudication and data management
-
Bioresorbable scaffold
501 patients, global
Services: core lab (OCT, IVUS, MSCT and QCA) and CEC adjudication
-
PCI and DAPT - click here for trial details
16,000 patients, global
Services: protocol, statistics, data management, monitoring, CEC adjudication, DSMB and Core Lab
-
Safety & efficacy dose finding trial NOAC
105 patients, Europe
Services: Monitoring, data management, CRF, CEC adjudication and DSMB
-
Coronary Artery Disease - Cardiotonic Agent
3,000 patients, Global
Services: CEC adjudication
-
Heart failure: CRT-D
3,796 patients, Global
Services: Core Lab (ECHO, Angio & ECG)
-
Left Atrial Appendage Occlusion
700 patients, Europe
Services: CEC adjudication
-
Transcatheter aortic valve implantation
1,000 patients, global
Services: Core Lab (ECHO)
-
Bioresorbable scaffold - click here for trial details
190 patients, Europe
Services: protocol, statistics, data management, monitoring, CEC adjudication, DSMB and Core Lab
-
PCI in three-vessel disease (3VD) - click here for trial details
450 patients, Europe
Services: protocol, statistics, data management, monitoring, CEC adjudication, DSMB and Core Lab